Prognostic factors in ovarian adult granulosa cell tumour

Miller, Keith; McCluggage, W. Glenn

doi:10.1136/jcp.2008.057604

Cited by 51 publications

(48 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evre I GHT tüm hastaların yaklaşık 60-90%'ını oluşturmakta olup bu grupta 5 yıllık genel sağkalım oranları 90-95% civarında bulunmuştur (16,17). Daha ileri evrelerde, evre II ve III/IV için 5 yıllık sağkalım oranları sırasıyla 55-75% ve 22-50% olarak raporlanmıştır (18,19).…”

Section: Discussionunclassified

The Clinicopathological Characteristics of Stage I Granulosa Cell Ovarian Cancer

Bozkaya¹,

Doğan²,

Demi̇rci³

et al. 2017

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETAmaç: Bu çalışmada kliniğimizdeki evre 1 over granüloza hücreli tümör (GHT) hastaların klinik verileri eşliğinde tedavi ve takip uygulamaları ile bunların sonuçları tartışılmıştır. Yöntem: Temmuz 2006 -Aralık 2015 yılları arasında kliniğimizde evre 1 GHT tanısı alan 15 hasta klinikopatolojik özellikleri, uygulanan tedaviler ve uzun süreli takip sonuçları açısından değerlendirilmiştir. Bulgular: Medyan yaşı 52 (24-71) idi. FIGO Evreleme Sistemine göre 9 hasta evre IA iken 6 hasta evre IC idi. Hastaların yarısı (53.3%) uterin kanama ile başvurdu. En sık (73.3%) yerleşim yeri ise sol over idi. Cerrahi tedavi olarak 10 hastaya total abdominal histerektomi+ bilateral salpingooferektomi+bilateral pelvik-paraaortik lenf nodu diseksiyonu+omentektomi, 2 hastaya sadece total abdominal histerektomi+bilateral salpingooferektomi ve 3 hastaya ise fertilite koruyucu cerrahi uygulanmıştı. 3 hastada perinöral invazyon (PNI) ve 2 hastada lenfovasküler invazyon (LVI) saptandı. Endometrium histopatolojik değerlendirilmesinde, 6 hasta ile en fazla basit atipisiz hiperplazi saptandı. Toplam yedi hastaya adjuvan tedavi olarak 3 kür [Bleomisin, Etoposid, Sisplatin (BEP)] kemoterapi rejimi verildi. Medyan takip süresi 77.9 ay (4.1-108.5 ay) ve genel sağkalım 77.9 ay (95% CI, 39.6-116.3) idi. Takiplerde hiçbir hastada nüks gelişmedi. Sonuç: Over GHT nadir görülmektedir. Erken evre hastalarda adjuvan tedavi uygulanacak hastaları belirlemek üzere yüksek riskli grubunu saptamak için randomize çok merkezli prospektif çalışmalara ihtiyaç vardır. Anahtar Kelimeler: Over granüloza hücreli tümör, histerektomi, salpingooferektomi, adjuvan kemoterapi ABSTRACT Introduction: We aimed to evaluate the clinicopathological characteristics of patients with stage 1 granulosa cell ovarian carcinoma (GCOC). Methods: Between July 2006 -December 2015, the clinical and pathological parameters, treatment features and long term follow up outcomes of 15 patients with stage 1 GCOC were evaluated retrospectively. Results: Median age was 52 (24-71).According to FIGO staging system, 9 patients had stage 1A disease and 6 patientshad stage IC GCOC. Half of (53.3%) of the patients presented with uterine bleeding (53.3%) and left over (73.3%) was the most common localization. Ten patients had abdominal hysterectomy-bilateral salphingoopherectomy-pelvic paraaortic lymph node dissection-omentectomy and whereas 3 patients had total abdominal hysterectomy-bilateral salphingoopherectomy and 2 patients had fertility sparing surgery as a surgical procedure. 3 patients had perineural invasion, 2 patients had lymphovascular invasion.Histopathological evaluation of endometrium revealed simple hyperplasia without atypia in 6 patients. As adjuvant setting, 7 patients received 3 cycles of chemotherapy [bleomycin +etoposid+ cisplatin (BEP)]. Median follow up was 77.9 months (4.1 max=18.5 month) and median overall survival was 77.9 ay (95% CI, 39.6-116.3). None of the patients relapsed durring follow-up. Conclusion: Over granulosa cell carcinoma is rare. Randomized prospective clin...

show abstract

Section: Discussionunclassified

The Clinicopathological Characteristics of Stage I Granulosa Cell Ovarian Cancer

Bozkaya¹,

Doğan²,

Demi̇rci³

et al. 2017

Acta Oncol Tur.

View full text Add to dashboard Cite

show abstract

“…However, AGCT has a distinct and well‐known propensity for late recurrence and metastasis, with a protracted clinical course. Up to one‐third of women relapse, and 70–80% of patients with recurrences will succumb to their disease . Given this low‐grade malignant behaviour and propensity for late recurrence and metastasis, which is in contrast to most other SCSTs, which are benign (or when malignant recur early), it is important to make an accurate diagnosis of AGCT, as long‐term follow‐up is required.…”

Section: Rare Gynaecological Neoplasms and Their Mutated Genesmentioning

confidence: 99%

Recently characterized molecular events in uncommon gynaecological neoplasms and their clinical importance

2016

View full text Add to dashboard Cite

The introduction of new sequencing technologies has resulted in the discovery of commonly mutated genes in uncommon cancers, including non-epithelial ovarian neoplasms and other rare gynaecological tumours, such as cervical embryonal rhabdomyosarcoma. In some of these neoplasms, mutations in certain genes are both frequent and specific enough for the genomic mutations and sometimes their associated protein loss or overexpression to be used as an aid to diagnosis. In this review, we contrast previous gene identification methods with newer ones, and discuss how the new sequencing technologies (collectively referred to as 'next-generation sequencing') have permitted the identification of specific molecular events that characterize several rare gynaecological neoplasms. We highlight the value of using sequencing to complement traditional pathological methods when diagnosing certain tumours, and provide practical advice to pathologists dealing with these neoplasms. We focus on adult granulosa cell tumours (somatic monoallelic mutations in FOXL2), Sertoli-Leydig cell tumours, gynaecological embryonal rhabdomyosarcomas (germline and somatic mutations in DICER1), and small-cell carcinoma of the ovary, hypercalcaemic type (biallelic mutations in SMARCA4). The new genetic findings provided by next-generation sequencing in these uncommon neoplasms have brought these disorders back into focus, and point the way towards new diagnostic, preventive and therapeutic avenues.

show abstract

“…This can be particularly important in patients who are receiving chemotherapy and RT. 234,235 Patients with disease spread outside the ovary (stages II to IV) are traditionally treated with postoperative adjuvant chemo, although benefits are unproven. Inhibin is a tumor marker that is secreted by some granulosa cell tumors.…”

Section: Immature Teratomamentioning

confidence: 99%